



WEEKLY EPIDEMIOLOGICAL REPORT

A publication of the Epidemiology Unit

Ministry of Health

231, de Saram Place, Colombo 01000, Sri Lanka

Tele: + 94 11 2695112, Fax: +94 11 2696583, E mail: epidunit@sltnet.lk

Epidemiologist: +94 11 2681548, E mail: chepid@sltnet.lk

Web: http://www.epid.gov.lk

Vol. 51 No. 44

26th Oct - 01st Nov 2024

Immunization Anxiety; prevent, identify and respond to stress-related responses following immunization

Vaccination is a cornerstone of public health, preventing millions of deaths and keeping populations safe from vaccine-preventable diseases. Immunization is recognized as an essential element of the human right to health, serving as a vital means to protect individuals and communities from infectious diseases. It has significantly contributed to the control, elimination, and eradication of many life-threatening diseases, underscoring its importance in safeguarding public health. This phenomenon, often referred to as Immunization Stress-Related Responses (ISRR), involves various stress reactions associated with vaccination, both physical and psychological. Understanding immunization anxiety and implementing effective management strategies can help maintain public trust and ensure the success of immunization programs.

However, despite its success, immunization can trigger anxiety in individuals, particularly as certain diseases become less common and public attention shifts toward potential vaccine side effects. Adverse Events Following Immunization (AEFIs), though rare, can undermine public trust in vaccines if not effectively addressed. Therefore, ensuring transparent communication, prompt investigation, and proper management of AEFIs is crucial to maintaining confidence in immunization programs. Managing these stress responses is necessary to prevent the spread of fear and misconceptions, especially during mass immunization campaigns or when new vaccines are introduced.

Adverse Events Following Immunization (AEFI)

According to the World Health Organization (WHO), an AEFI is considered any unexpected medical occurrence following immunization, even if it is not causally linked to the vaccine. There are five main AEFI categories:

- Reaction to the vaccine product: Symptoms directly resulting from the vaccine's components.
- Reaction to a vaccine quality defect: Symptoms due to a quality issue in vaccine

production.

- Immunization error: Symptoms caused by errors in vaccine storage, handling, or administration.
- Immunization anxiety: Responses related to stress or anxiety triggered by immuniza-
- Coincidental events: Health events unrelated to the vaccine but occurring after immunization.

The proper identification of AEFI categories is essential to distinguish actual adverse effects from unrelated events, and implementation of measures to avoid them in the future and remove unnecessary fears about vaccine safety.

Stress-Related **Immunization** Responses (ISRR):

ISRR refers to the range of stress responses triggered by the vaccination process. Previously termed "immunization anxiety-related reactions," ISRR comprises both psychological and physiological responses before, during, and after immunization, influenced by individual and social factors. For example, anxiety, fear of needles and social influences like media coverage can contribute to ISRR.

ISRR reactions may also appear in clusters within a community, especially when large groups receive vaccinations simultaneously. These clusters can generate public concern, which might disrupt immunization efforts and lead to vaccine hesitancy. Hence, identifying and managing ISRR effectively is critical for maintaining confidence in immunization pro-

Types of ISRR:

Immunization stress-related responses vary in type and severity.

Acute stress response: Often termed as the "fight or flight" response, it involves an intensified state of physiological alertness. Symptoms may include increased heartbeat, palpitation, and hyperventilation. The

Contents	Page
Immunization Anxiety; prevent, identify and respond to stress-related responses following immunization	; 1
	3
2. Summary of selected notifiable diseases reported $(19^{th} - 25^{th} Oct 2024)$	4
3. Surveillance of vaccine preventable diseases & AFP (19th – 25th Oct 2024)	

- sympathetic nervous system drives this response as the body prepares to face a perceived threat.
- 2. Vasovagal reaction: This response may result in dizziness or faintishness due to a sudden drop in heart rate and blood pressure. Symptoms can consist of nausea, sweating, and pallor, with a rapid recovery. Syncope (fainting) and even syncopal seizures are common in adolescents.
- 3. Dissociative neurological symptom reactions (DNSRs):

 DNSRs may involve non-epileptic seizures or other physical symptoms without a clear neurological cause. Past trauma, anxiety, or high stress levels can trigger DNSRs, which, while typically transient, may sometimes persist under continuous stress.
- 4. **Non-epileptic seizures**: These seizures resemble epileptic events but do not involve the neurological discharges associated with epilepsy. In high-stress situations, these are involuntary responses linked to autonomic arousal.

The impact of ISRR on immunization:

ISRR incidents can affect public confidence in vaccines, particularly when they occur in clusters, as seen in school-based HPV vaccination programs. For instance, syncope is more frequent in adolescent girls receiving the HPV vaccine, which has led to hesitation or anxiety about the vaccine's safety. Additionally, when immunization anxiety is improperly managed, it may intensify public uncertainty, further complicating vaccination efforts.

Preventing and managing ISRR:

Healthcare workers have a critical role in preventing and managing ISRR. Preventive strategies include identifying individuals at risk for immunization anxiety and providing supportive communication throughout the immunization process. Other measures, such as creating a calm, private immunization environment and managing social influences, can also reduce ISRR risk.

Pre-immunization measures:

- Identifying at-risk individuals: Certain individuals, including those aged 10-19 or with a history of vasovagal syncope or anxiety, are more prone to immunization anxiety. A brief medical history can help identify those at risk, allowing healthcare providers to take suitable interventions.
- Environmental preparation: A calm, ordered setting with controlled noise and privacy can lower anxiety levels. These adjustments

During immunization:

- 1. Supportive communication: Communicating calmly and explaining the procedure without using fear-inducing terms like "pain", "needle" or "puncture" can help reduce anxiety. For instance, using neutral language to signal the beginning of an injection and providing reassurance throughout the process can be helpful.
- 2. **Proper positioning**: Seating or lying down individuals can help manage fainting episodes. For children and adolescents, a seated position with support from a parent or caregiver can help lower stress levels.
- Use of distraction: Distraction techniques, such as engaging in conversations about favourite topics or breathing exercises, are effective for reducing stress, particularly in school-age children and adolescents.

Post-immunization management:

Differentiating ISRR from other reactions: Clear communication is essential to differentiate ISRR from serious adverse events like anaphylaxis, reassuring individuals and families that ISRR symptoms are generally benign and

- resolved on their own.
- Education: Providing accurate information about ISRR to individuals and caregivers post-immunization can help prevent overreaction to symptoms and encourage confidence in the vaccination process.

The following approaches are based on guidelines from the WHO for reducing pain and managing anxiety during immunization, especially for school-age children, adolescents, and adults.

1. Communication:

- Use neutral language to describe the procedure across all age groups.
- Encourage distraction by talking about topics unrelated to the procedure (e.g., favourite foods or events for children, school for adolescents, and work or holidays for adults).
- Avoid saying "It won't hurt" and provide simple, calm reassurances without excessive repetition.

2. Physical positioning:

- Children, adolescents, and adults should generally remain upright unless there's a risk of fainting.
- Muscle tension techniques are recommended to reduce vasovagal responses.

3. Distraction and breathing techniques:

- Age-appropriate distraction strategies, such as stories or bubbles for children, should be used. For adolescents, techniques such as listening to music or engaging them in casual conversation about a topic of interest (e.g., hobbies, sports, or upcoming events) can serve as effective distractions.
- Adolescents and adults can use breathing techniques, like coughing or taking deep breaths, to reduce pain.

Communication strategies to sustain public trust:

Immunization anxiety poses a significant challenge to the success of vaccination programs, especially as vaccine-preventable diseases become less common and public awareness of AEFIs increases. Effective communication strategies and proactive management of ISRR are crucial to maintaining public trust in vaccines. Training healthcare providers to handle ISRR cases tactfully, addressing incidents promptly, and implementing environmental adjustments and tailored communication approaches ensure that immunization programs continue to foster confidence and protect communities from preventable diseases

Compiled by:

Dr Aruni Hathamuna Senior Registrar Epidemiology Unit

References:

- Immunization stress-related response: a manual for program managers and health professionals to prevent, identify and respond to stress-related responses following immunization. Www.who.int. https://www.who.int/publications/i/item/9789241515948
- 2) World Health Organization. (2019). Immunization stressrelated response: a manual for program managers and health professionals to prevent, identify and respond to stress -related responses following immunization. Who.int. https://doi.org/9789241515948

Table 1: Selected notifiable diseases reported by Medical Officers of Health 19th - 25th Oct 2024 (43rd Week)

Tal	ole	Table 1: Selected notifiable diseases reported by Medical Officers of Health 19th - 25th Oct 2024 (43rd V												(43	rd V	/eek)												
CD	*	100	100	100	100	100	100	100	100	100	93	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	66	
WRCD	*	100	29	100	100	92	100	100	100	88	100	100	100	75	100	100	98	100	100	92	87	100	100	82	82	100	100	94	
sisolr	α	1819	266	494	528	108	234	379	131	146	227	25	26	34	30	139	105	105	424	186	243	91	213	106	315	313	126	7508	
Tuberculosis	٥	43	0	0	0	4	2	2	0	4	2	0	0	0	0	2	_	0	0	4	က	0	7	_	_∞	2	4	113	
ınia-	α	2	25	7	22	308	_	4	441	104	_	_	_	10	13	4	22	18	561	34	622	447	39	227	150	26	0	3275	
Leishmania-	٥	0	7	0	-	12	0	0	7	0	0	0	0	_	0	0	0	0	ω	_	တ	4	0	2	~	7	0	48 3	
gitis	α	42	125	22	13	20	17	82	28	20	30	9	2	24	2	45	36	22	245	72	22	30	37	94	122	89	17	1369	
Meningitis	٥	4	2	_	0	~	0	_	_	_	0	0	0	_	0	0	0	0	4	2	7	0	7	0	က	က	_	35 1	
xodu	α	200	406	572	361	136	228	726	281	328	204	12	10	41	0	130	116	82	526	121	262	135	341	152	332	784	209	7004	
Chickenpox	٥	15	4	25	2	~	9	29	4	9	~	0	0	0	~	9	4	2	17	~	က	2	13	4	4	20	2	185	
H. Rabiies	α	0	0	_	က	0	0	_	2	0	_	2	0	0	7	7	~	0	4	_	_	~	0	_	7	_	0	26	
H.	٥	0	0	0	_	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	_	
Viral Hep.	α	ე ე	7	7		∞	0	10	7	23	7	0	~	4	0	23	2	က	∞	4	14	54	45	20	28	12	4	361	
Vira	٥	0	~	0	0	0	0	0	0	က	0	0	0	0	0	2	0	0	~	0	0	2	_	5	0	0	0	15	
Typhus F.	α			∞	33	9	41	112	47	27	477	1	13	5		2	2	12	30	36	30	2	43	31	30	30	2	1063	
			0	0	2	_	7	2	_	2	5	0	0	0	0	0	0	0	0	_	0	0	က	0	က	0	0	22	
Leptospirosis	α	,	748	740	229	92	155	792	429	200	18	20	27	98	89	70	174	138	618	227	394	239	450	297	1729	692	29	9773	
Lepto	٥		9	13	6	4	က	21	7	32	0	_	2	5	0	_	_	2	28	2	9	2	9	က	22	31	0	318	
F. Poisoning	α	22	77	37	59	27	208	101	48	28	47	2	9	22	78	64	23		351	9	43	31	56	86	31	14	28	1443	
F. Po	٥	0	0	0	0	0	က	3	0	0	12	0	0	0	0	0	0	0	0	0	0	2	0	0	<u></u>	0	0	24	
Fever	α	49	4	36	6	∞		12	9	2	27	2	<u></u>	2	0	7	0	3	က	က	2	~	00	က	6	10	2	230	
E.	٥	< -	0	0	0	0	_	0	~	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	~	0	0	4	
Encephalitis	α	, , =	35	2	5	_	7	22	4	9	2	0	0	_	0	15	4	_	35	4	9	က	0	5	∞	10	0	196	
Ence	٥	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	_	0	0	0	0	0	_	_	0	_	0	9	
Dysentery	α	35	39	30	34	17	130	47	28	1	62	17	4	13	တ	116	33	16	47	11	33	26	36	19	106	26	17	972	
Dys	٥	0	~	_	0	3	က	2	0	~	3	0	0	0	0	~	~	0	0	0	0	4	_	_	4	က	0	29	
Fever	α	9893	4684	2436	3953	742	319	1860	759	1030	5289	292	294	171	206	1467	243	644	2033	1031	675	357	772	843	2509	1813	683	44998	
Dengue Fever	٥	161	86	31	74	43	4	21	0	29	7	~	7	_	~	7	က	4	21	15	9	9	41	28	24	24	က	672	
RDHS		Colombo	Gampaha	Kalutara	Kandy	Matale	Nuwara Eliya	Galle	Hambantota	Matara	Jaffna	Kilinochchi	Mannar	Vavuniya	Mullaitivu	Batticaloa	Ampara	Trincomalee	Kurunegala	Puttalam	Anuradhapura	Polonnaruwa	Badulla	Monaragala	Ratnapura	Kegalle	Kalmunai	SRILANKA	

Source: Weekly Returns of Communicable Diseases (esurvillance.epid.gov.Ik). T=Timeliness refers to returns received on or before 25th Oct, 2024 Total number of reporting units 358 Number of reporting units data provided for the current week. B = Cumulative cases for the year.

Table 2: Vaccine-Preventable Diseases & AFP

19th - 26th Oct 2024 (43rd Week)

Disease	No. of Cases by Province									Number of cases during current	Number of cases during same	Total number of cases to date in	Total num- ber of cases to date in	Difference between the number of cases to date	
	W	С	S	N	Е	NW	NC	U	Sab	week in 2024	week in 2023	2024	2023	in 2024 & 2023	
AFP*	02	01	00	00	00	00	00	00	00	02	02	65	79	-17.7%	
Diphtheria	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %	
Mumps	02	00	01	00	00	04	00	00	00	07	05	243	201	20.9 %	
Measles	00	00	00	00	01	00	00	00	00	01	39	287	677	-57.6 %	
Rubella	00	00	00	00	00	00	00	00	00	00	00	02	08	-75%	
CRS**	00	00	00	00	00	00	00	00	00	00	00	00	02	-100 %	
Tetanus	00	00	00	00	00	00	00	00	00	00	00	05	06	-16.6 %	
Neonatal Tetanus	00	00	00	00	00	00	00	00	00	00	02	00	00	0 %	
Japanese Enceph- alitis	00	00	00	00	00	00	00	00	00	00	00	11	02	450 %	
Whooping Cough	00	00	00	00	00	00	00	00	00	00	00	56	07	700 %	

Key to Table 1 & 2

Provinces: W: Western, C: Central, S: Southern, N: North, E: East, NC: North Central, NW: North Western, U: Uva, Sab: Sabaragamuwa.

RDHS Divisions: CB: Colombo, GM: Gampaha, KL: Kalutara, KD: Kandy, ML: Matale, NE: Nuwara Eliya, GL: Galle, HB: Hambantota, MT: Matara, JF: Jaffna,

KN: Killinochchi, MN: Mannar, VA: Vavuniya, MU: Mullaitivu, BT: Batticaloa, AM: Ampara, TR: Trincomalee, KM: Kalmunai, KR: Kurunegala, PU: Puttalam,

AP: Anuradhapura, PO: Polonnaruwa, BD: Badulla, MO: Moneragala, RP: Ratnapura, KG: Kegalle.

Data Sources:

Weekly Return of Communicable Diseases: Diphtheria, Measles, Tetanus, Neonatal Tetanus, Whooping Cough, Chickenpox, Meningitis, Mumps., Rubella, CRS,

Special Surveillance: AFP* (Acute Flaccid Paralysis), Japanese Encephalitis

CRS** =Congenital Rubella Syndrome

NA = Not Available

Take prophylaxis medications for leptospirosis during the paddy cultivation and harvesting seasons.

It is provided free by the MOH office / Public Health Inspectors.

Comments and contributions for publication in the WER Sri Lanka are welcome. However, the editor reserves the right to accept or reject items for publication. All correspondence should be mailed to The Editor, WER Sri Lanka, Epidemiological Unit, P.O. Box 1567, Colombo or sent by E-mail to chepid@sltnet.lk. Prior approval should be obtained from the Epidemiology Unit before publishing data in this publication

ON STATE SERVICE